Danaher Corporation has announced today the completion of the sale of some of its businesses to Sartorius AG for a consideration of $825 million. The sale was a requirement in order to obtain regulatory approval for Danaher’s acquisition of the GE Biopharma business, now called Cytiva. The sale included its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards, single use tangential flow filtration systems, and stainless steel hollow fiber tangential flow filtration systems businesses.
Sartorius’ CEO Dt. Joachim Kreuzburg said, “The acquisition of this portfolio is a further milestone for Sartorius. The assets we purchased are an excellent strategic and operational fit with both our divisions. We are very pleased to welcome approximately 300 new Sartorius employees and to combine our expertise to become even more relevant together for our biopharma and life science customers.”